A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma

Sveva Castelli, Tim Flaadt, Franziska Schulze, Theresa M. Thole-Kliesch, Felix Zirngibl, Lena Oevermann, Annette Künkele, Kathy Astrahantseff, Stefanie Schulte, Louisa Duell, Joerg Fuchs, Thorsten Simon, Barbara Hero, Patrick Hundsdoerfer, Julian M. M. Rogasch, Peter Lang, Steven Warmann, Arend von Stackelberg, Johannes H. Schulte, Angelika Eggert, Hedwig E. Deubzer

Open source

DOI: 10.1038/s41409-026-02912-2
Published: 2026-05-29
Container: Bone Marrow Transplantation
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41409-026-02912-2,
  title = {A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma},
  author = {Sveva Castelli and Tim Flaadt and Franziska Schulze and Theresa M. Thole-Kliesch and Felix Zirngibl and Lena Oevermann and Annette Künkele and Kathy Astrahantseff and Stefanie Schulte and Louisa Duell and Joerg Fuchs and Thorsten Simon and Barbara Hero and Patrick Hundsdoerfer and Julian M. M. Rogasch and Peter Lang and Steven Warmann and Arend von Stackelberg and Johannes H. Schulte and Angelika Eggert and Hedwig E. Deubzer},
  year = {2026},
  journal = {Bone Marrow Transplantation},
  doi = {10.1038/s41409-026-02912-2},
  url = {https://doi.org/10.1038/s41409-026-02912-2}
}

RIS

TY  - JOUR
TI  - A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma
AU  - Sveva Castelli
AU  - Tim Flaadt
AU  - Franziska Schulze
AU  - Theresa M. Thole-Kliesch
AU  - Felix Zirngibl
AU  - Lena Oevermann
AU  - Annette Künkele
AU  - Kathy Astrahantseff
AU  - Stefanie Schulte
AU  - Louisa Duell
AU  - Joerg Fuchs
AU  - Thorsten Simon
AU  - Barbara Hero
AU  - Patrick Hundsdoerfer
AU  - Julian M. M. Rogasch
AU  - Peter Lang
AU  - Steven Warmann
AU  - Arend von Stackelberg
AU  - Johannes H. Schulte
AU  - Angelika Eggert
AU  - Hedwig E. Deubzer
PY  - 2026
JO  - Bone Marrow Transplantation
DO  - 10.1038/s41409-026-02912-2
UR  - https://doi.org/10.1038/s41409-026-02912-2
ER  -

APA

Castelli, S., Flaadt, T., Schulze, F., Thole-Kliesch, T. M., Zirngibl, F., Oevermann, L., Künkele, A., Astrahantseff, K., Schulte, S., Duell, L., Fuchs, J., Simon, T., Hero, B., Hundsdoerfer, P., Rogasch, J. M. M., Lang, P., Warmann, S., Stackelberg, A. V., Schulte, J. H., Eggert, A., & Deubzer, H. E. (2026). A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-026-02912-2

Source records

crossref · retrieved 2026-09-26T13:15:29.012Z